Alternative Splicing Factor/Splicing Factor 2 Regulates the Expression of the ζ Subunit of the Human T Cell Receptor-associated CD3 Complex*

T cells from patients with systemic lupus erythematosus express decreased levels of the T cell receptor-associated CD3 ζ chain, a feature directly linked to their aberrant function. The decrease in CD3ζ protein expression is in part due to decreased levels of functional wild type isoform of the 3′-untranslated region (UTR) of CD3ζ mRNA with concomitant increased levels of an unstable alternatively spliced isoform. In order to identify factors involved in the post-transcriptional regulation of CD3ζ, we performed mass spectrometric analysis of Jurkat T cell nuclear proteins “pulled down” by a CD3ζ 3′-UTR oligonucleotide, which identified the splicing protein alternative splicing factor/splicing factor 2 (ASF/SF2). We show for the first time that ASF/SF2 binds specifically to the 3′-UTR of CD3ζ and regulates expression of CD3ζ protein by limiting the production of the alternatively spliced isoform. During activation of human T cells, an increase in the wild type CD3ζ mRNA is associated with increased expression of ASF/SF2. Finally, we show a significant correlation between ASF/SF2 and CD3ζ protein levels in T cells from systemic lupus erythematosus patients. Thus, our results identify ASF/SF2 as a novel factor in the regulation of alternative splicing of the 3′-UTR of CD3ζ and protein expression in human T cells.

T cells from patients with systemic lupus erythematosus express decreased levels of the T cell receptor-associated CD3 chain, a feature directly linked to their aberrant function. The decrease in CD3 protein expression is in part due to decreased levels of functional wild type isoform of the 3-untranslated region (UTR) of CD3 mRNA with concomitant increased levels of an unstable alternatively spliced isoform. In order to identify factors involved in the post-transcriptional regulation of CD3, we performed mass spectrometric analysis of Jurkat T cell nuclear proteins "pulled down" by a CD3 3-UTR oligonucleotide, which identified the splicing protein alternative splicing factor/splicing factor 2 (ASF/SF2). We show for the first time that ASF/SF2 binds specifically to the 3-UTR of CD3 and regulates expression of CD3 protein by limiting the production of the alternatively spliced isoform. During activation of human T cells, an increase in the wild type CD3 mRNA is associated with increased expression of ASF/SF2. Finally, we show a significant correlation between ASF/SF2 and CD3 protein levels in T cells from systemic lupus erythematosus patients. Thus, our results identify ASF/SF2 as a novel factor in the regulation of alternative splicing of the 3-UTR of CD3 and protein expression in human T cells.
Systemic lupus erythematosus (SLE) 2 is a chronic multisystem autoimmune disease characterized by abnormal cellular and humoral immune responses and a disease course marked by relapses (flares) and remissions. A key signaling defect of T cells in SLE patients is their aberrant expression of the T cell receptor (TCR)-associated CD3 chain, the crucial signaling transducer of the TCR (1). CD3 protein expression is heterogeneous in SLE patients and tends to inversely correlate with severity of the disease. Consequently, many patients exhibit decreased (20 -80% of normal) levels of CD3 protein, whereas others express normal levels of CD3 protein when compared with healthy individuals. The homologous Fc receptor ␥ chain replaces CD3 chain in the TCR CD3 complex in these CD3low T cells (2) and recruits the spleen tyrosine kinase (Syk) instead of the normally recruited -associated protein (ZAP-70) (3). This "rewiring" of the TCR, along with preclustered TCRbearing lipid rafts, leads to aberrantly increased phosphorylation and calcium flux upon activation (4). Despite this overexcitable phenotype, SLE T cells fail to produce the vital cytokine interleukin-2. Replenishment of the CD3 in the SLE T cells in vitro reverts this phenotype and more importantly restores interleukin-2 production (5). Although these findings highlight a central role for the aberrant CD3 expression in the SLE T cell defect, the mechanisms regulating the expression of CD3 chain in physiology and in disease are not fully understood.
The CD3 gene spans 31 kb in the chromosome 1q23.1 locus, a region associated with SLE susceptibility (6), and bears eight exons separated by introns ranging from 700 bp to greater than 8 kb (Fig. 1A, top) (7,8). The CD3 mRNA is a 1.472-kb spliced product of the eight exons with a coding region of 492 bp and an exon VIII-encoded long downstream 906-bp 3Ј-untranslated region (UTR) (Fig. 1A, middle). Activation of alternative splicing within the 3Ј-UTR due to usage of two internal (5Ј and 3Ј) splice sites results in splice deletion of 562 bases (nucleotides 672-1233), leading to the generation of a 344-bp alternatively spliced (AS) variant. We have shown that T cells from healthy individuals express predominantly the wild type (WT) isoform, whereas SLE T cells exhibit variably increased levels of the AS isoform (9). Because this alternative splicing affects the UTR and not the coding region, the size of the protein generated from these two isoforms is identical. However, because the 344-bp AS CD3 isoform lacks two critical regulatory adenosine/uridine-rich elements (ARE) and a translation regulatory sequence, the transcript stability and translation of this isoform are significantly lower than that of the 906-bp WT CD3 isoform; consequently, the relative amount of CD3 protein generated by the AS isoform is significantly lower than that from the WT isoform (10). Accordingly, the CD3 protein expression level directly correlates with the level of the WT isoform and inversely with the AS isoform (9). Although the differential expression of the CD3 3Ј-UTR isoforms contributes to differential levels of CD3 protein expression, the factor(s) regulating the alternative splicing of CD3 3Ј-UTR is unknown.
Alternative splicing is a powerful mechanism of gene regulation, which results in the generation of numerous transcripts and proteins from a single gene (11). Splice site selection is regulated by cis-acting elements, such as intronic and exonic splicing enhancer and silencer sequences, respectively, whereas trans-acting factors include the U small nuclear ribonucleoproteins, the heterogeneous nuclear ribonuclear proteins, and the serine-arginine (SR) family of splicing factors (12,13).
ASF/SF2 (alternative splicing factor/splicing factor 2) is a prototype member of the SR family of splicing proteins and has an N-terminal domain bearing two RNA recognition motifs and a C-terminal arginine-serine (RS) domain, which is involved in protein-protein interactions. ASF/SF2 is a predominantly nuclear protein but is known to shuttle between the cytoplasm and nucleus (14). Phosphorylation and dephosphorylation are important in the splicing function of ASF/SF2 and affect its cellular localization and function (15). The serine/ threonine-specific protein phosphatase PP1 is shown to dephosphorylate ASF/SF2 in response to treatment with the sphingolipid metabolite ceramide and thus regulate alternative splicing of the apoptosis-related caspase-9 pre-mRNA (16). ASF/SF2 binds pre-mRNA and can activate or repress splicing, thus promoting exon deletion or exon inclusion in alternative splicing (17,18). ASF/SF2 regulates the alternative splicing of eukaryotic genes such as caspase-9 (19), vascular endothelial growth factor (20), and the T cell differentiation marker CD45 (21).
In order to identify factors involved in the post transcriptional regulation of CD3, we performed mass spectrometric analysis of Jurkat T cell nuclear proteins "pulled down" by a CD3 3Ј-UTR-defined ARE-bearing oligonucleotide that identified the splicing factor ASF/SF2. We hypothesized that ASF/ SF2 regulates the alternative splicing of the 3Ј-UTR of CD3 and thus regulates the expression of the CD3 protein. We show for the first time that ASF/SF2 binds to the 3Ј-UTR of CD3 and regulates the shift in alternative splicing from the AS to the WT isoform and regulates expression of CD3 protein.
We also show that a preferential increase in the WT CD3 isoform occurs during T cell stimulation, which correlates with increased ASF/SF2 expression levels. Last, ASF/SF2 expression correlates directly with CD3 chain levels in T cells from SLE patients.

EXPERIMENTAL PROCEDURES
Patients and Controls-Twelve female SLE patients fulfilling the American College of Rheumatology classification criteria (22) and 10 healthy subjects (age-, race-, and gender-matched) as controls were chosen for this study. For some studies, other healthy volunteers were used. The study protocol was approved by the health use committees of Beth Israel Deaconess Medical Center. Written informed consent was obtained from all participating subjects.
Mass Spectrometry Protein Identification-Peptide sequencing and protein identification were performed by the core facility at Beth Israel Deaconess Medical Center (23).
Cells, Plasmids, and Antibodies-Peripheral blood was collected by venipuncture and T cells purified using the Rosette Sep T cell kit (StemCell Technologies). The pcDNA3.1-ASF/SF2 vector was a kind gift from Dr. James Manley (Columbia University, New York). ASF/SF2 antibody was from Zymed (Invitrogen). CD3, and goat anti-mouse horseradish peroxidase-conjugated antibody were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). ␤-Actin antibody was from Sigma, and ␤-tubulin antibody was from Upstate. D-erythro-C 6 -ceramide was from Matreya LLC (Pleasant Gap, PA).
RNA Electrophoretic Mobility Shift Assays-RNA oligonucleotides were end labeled with [ 32 P]ATP (PerkinElmer Life Sciences) in a 10ϫ T4 kinase buffer with T4 polynucleotide kinase for 1 h at 37°C. The reaction was stopped with Tris-HCl, pH 8.0, buffer, and radiolabeled probes were separated by microspin columns (GE Healthcare). T cell nuclear extracts were incubated with antibody in a 5ϫ high density TBE buffer with 1 N KCl, 500 g of poly(dI⅐dC), and RNAsin on ice for 15 min. 20 pmol of [ 32 P]ATP-labeled probes were added, and reaction mixtures were kept at room temperature for 15 min and run on a 6% retardation gel. Gels were fixed in a 10% acetic acid and 10% methanol solution, dried, and exposed overnight to a phosphor screen and scanned with a phosphor imager scanner (GE Healthcare).
In Vitro Transcription and Translation-The pASF expression plasmid (1.5 g) was used to transcribe and translate ASF/ SF2 using the TNT T7 quick coupled transcription/translation kit (Promega) according to manufacturer's instructions.
Plasmid Transfections-Transient transfections of peripheral blood T cells and were carried out using the Lonza Nucleofector system (Lonza, Walkersville, MD). Briefly, 5 ϫ 10 6 cells were resuspended in 100 l of Nucleofector solution, plasmid DNA (2 g/10 6 cells) was added, and cells were transfected using the nucleofector U-014 program. Cells were rescued immediately after transfection in prewarmed RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin in 12-well culture plates. Cells were harvested, and total RNA and protein was extracted 24 -48 h post-transfection.
Short Interfering RNA (siRNA) Knockdown-A pair of siRNAs against ASF/SF2 Hs_SFRS1_1 (target sequence CAG TAT TGA CCT TAT ACT AAA) and Hs_SFRS1_3 (target sequence ATC CAA CAA GAT AGA GTA TAA) and control non-silencing siRNA (target sequence AAT TCT CCG AAC GTG TCA CGT) were purchased from Qiagen (Valencia, CA). siRNA knockdown experiments were carried out using the Lonza Nucleofector system as described above.
Western Blotting-Cells were pelleted and lysed with radioimmunoprecipitation buffer (Boston Bioproducts). Lysates were resolved on 4 -12% BisTris gels and transferred to polyvinylidene difluoride membrane. Membranes were blocked with 5% nonfat milk in Tris-buffered saline with Tween 20 (TBS-T) for 1 h, incubated with primary antibody (1:1000) for 1 h, washed three times with TBS-T, incubated with horseradish peroxidase-conjugated secondary antibody (1:2000) for 1 h, washed three times with TBS-T, developed with ECL reagents (GE Healthcare), and visualized by the Fujifilm LAS-4000 imager.
mRNA Expression Studies-Total RNA was isolated using the RNeasy minikit (Qiagen, CA). 100 ng of total RNA was reverse transcribed into single-stranded cDNA using the avian myeloblastosis virus reverse transcriptase kit (Promega, Madison, WI). CD3 3Ј-UTR primers were as follows: forward, 5Ј-CAGCCAGGGGATTTCCACCACTCAAAG-3Ј (sense bp 567-592); reverse, 5Ј-CCCTAGTACATTGACGGGT-TTTTCCTG-3Ј (antisense bp 1472-1443), according to the numbering of Weissman et al. (24). GAPDH primers were 5Ј-CAACTACATGGTTTACATGTTCC-3Ј (forward) and 5Ј-GGA-CTGTGGTCATGAGTCCT-3Ј (reverse). ASF/SF2 primers were 5Ј-TCTCTGGACTGCCTCCAAGT-3Ј (forward) and 5Ј-GGCTTCTGCTACGACTACGG-3Ј (reverse). PCR amplification was carried out in a Bio-Rad thermocycler as follows: denaturation at 94°C for 5 min; 40 cycles of amplification with denaturation at 95°C for 45 s, annealing at 67°C for 1 min, and extension at 72°C for 2 min; a final extension at 72°C for 7 min; and final cooling at 4°C. PCR products were run on 1.2% agarose gels in 1ϫ Tris-acetate EDTA buffer, stained with ethidium bromide, and scanned with a Bio-Rad gel viewer. Real time PCR amplification of ASF/SF2 was carried out in a LightCycler 480 (Roche Applied Science) as follows: initial denaturation at 95°C for 5 min, 40 cycles of amplification (denaturation at 95°C for 15 s, annealing at 60°C for 15 s, and extension at 72°C for 30 s); 1 cycle of melting curves at 95°C for 15 s, 65°C for 2 min, and 97°C continuous; and a final cooling step at 37°C for 30 s. Threshold cycles (Ct) values were used to calculate relative mRNA expression by the ⌬⌬Ct relative quantification method.
Densitometry and Statistical Analysis-Densitometric analysis of the Western blots and agarose gels was performed with the Quantity 1 software (Bio-Rad). Statistical analyses were performed using Student's t test (MS Excel) and Pearson's R correlation coefficient (GraphPad Prism software, version 5.0).

Identification of ASF/SF2 Binding to the CD3 3Ј-UTR-The
3Ј-UTR of CD3 bears three AREs at positions 636, 705, and 985, designated ARE1, ARE2, and ARE3, respectively. We have shown that ARE2 and ARE3 are critical in stabilizing the CD3 transcript (25), and using an ARE2-defined (nucleotides 693-717) RNA oligonucleotide with Jurkat T cell nuclear proteins "pulled down" several putative RNA-binding proteins in the 30 -60 kDa range (23). Interestingly, mass spectrometry analysis of the ϳ30-kDa protein complex revealed peptides that matched the amino acid sequence of the SR protein ASF/SF2 (Fig. 1B).
To confirm specific ASF/SF2 binding to the CD3 3Ј-UTR in primary T cells, we used the RNA oligonucleotide (nucleotides 693-717) (Fig. 1C) in an RNA electrophoretic mobility shift assay. Radiolabeled oligonucleotides were incubated with nuclear protein extract, and the RNA protein complexes were run on a retardation gel (Fig. 1C, lane 1). Using an antibody specific for ASF/SF2, we showed that the binding complex was diminished (Fig. 1C, lane 2), whereas incubation with an irrelevant control antibody did not affect the complex (Fig. 1C, lane 3). Using in vitro translated ASF/SF2 protein in the gel shift assay, we observed the binding complexes diminish in the presence of ASF/SF2 antibody compared with in the presence of control antibody (Fig. 1C, lanes 4 -6). Specific binding of ASF/SF2 was observed with the addition of increasing amounts of ASF/SF2 protein (Fig. 1C, lanes 7-11), and the binding complexes were outcompeted in the presence of excess "cold" oligonucleotide (Fig. 1C, lane 13) compared with that of a scrambled control oligonucleotide (Fig. 1C, lane 14). These results indicate specific binding of ASF/SF2 to the nucleotide 693-717 region of the CD3 3Ј-UTR.
ASF/SF2 Regulates the Expression of CD3 Protein-The finding that ASF/SF2 binds to the 3Ј-UTR of CD3 prompted us to determine whether ASF/SF2 regulates the expression of CD3 protein. To address this question, we used a plasmid to overexpress ASF/SF2 and specific siRNA to knock down ASF/ SF2 in primary T cells. Upon forced expression of ASF/SF2 (pASF), CD3 protein expression was significantly increased as compared with control (pcDNA) transfected cells (Fig. 2, A and  B). Conversely, CD3 protein expression decreased by 36 Ϯ 10% (p ϭ 0.01) upon ASF/SF2 knockdown with siRNA (siASF) as compared with cells transfected with control (siCtrl) siRNA (Fig. 2, C and D). These results indicate that ASF/SF2 expression levels correlate directly with CD3 protein expression in human T cells.
ASF/SF2 Represses Alternative Splicing of the Exon VIII-defined CD3 3Ј-UTR-The splicing regulatory activity of ASF/ SF2 depends on its phosphorylation status, and the sphingolipid metabolite D-erythro-C 6 -ceramide is shown to modulate the splicing activity of ASF/SF2 through a protein phosphatase 1-mediated dephosphorylation of ASF/SF2 (19). We treated T cells with increasing concentrations of ceramide and assessed its effect on CD3 UTR alternative splicing by reverse transcription (RT)-PCR. A primer pair spanning the 5Ј-and 3Ј-ends of the 3Ј-UTR (arrows P1 and P2 in Fig. 1A, top) was used to amplify both isoforms simultaneously. In Fig. 3A, we show that the alternative splicing of the CD3 3Ј-UTR is activated in a concentration-dependent manner, such that there is a gradual decline in the WT isoform and a concomitant increase in the AS isoform. At the 30 M concentration, a clearly discernible effect on the alternative splicing is observed, and this ceramide dose was chosen for the next set of experiments. To specifically determine the role of ASF/SF2 in CD3 3Ј-UTR alternative splicing, we overexpressed ASF/SF2 in T cells and analyzed the expression of the CD3 3Ј-UTR splice isoforms by RT-PCR. As compared with control (pcDNA) transfected T cells (Fig. 3B,  lanes 1-3), ASF/SF2 overexpression led to a repression of alter-native splicing, causing an increase in the WT isoform and a parallel decrease in the AS isoform (Fig. 3B, lanes 4 -6). The ratio of the WT to AS isoforms thus increased by 40 Ϯ 20% (p ϭ 0.01) in the ASF/SF2-transfected cells (Fig. 3C). Ceramide treatment activated 3Ј-UTR splicing to generate decreased levels of the WT isoform (Fig. 3B, lanes 7-9), whereas reconstitution of ASF/SF2 in the ceramide-treated cells led to a restoration of the WT isoform (Fig. 3B, lanes 10 -12). These results show that ASF/SF2 represses the alternative splicing of CD3 3Ј-UTR to favor generation of the functional WT isoform over the faulty AS isoform.
Increased ASF/SF2 Levels Are Associated with Increased WT CD3 mRNA during T Cell Activation-Because CD3 is a critical initiator of the TCR-mediated signaling, we asked whether its expression during T cell activation is regulated by the 3Ј-UTR alternative splicing. We activated T cells for 0, 3, 6, 24, 48, and 72 h and measured expression of the CD3 3Ј-UTR splice variants. There was a rapid and prolonged increase in the WT CD3 isoform and a proportionate decrease in the AS isoform of CD3 (Fig. 4, A and B). Concomitantly, ASF/SF2 expression levels increased gradually over the 72 h of activation   APRIL 23, 2010 • VOLUME 285 • NUMBER 17 ( Fig. 4, C and D). These results further suggest that ASF/SF2 expression promotes the production of the WT CD3 mRNA levels rather than the AS CD3 isoform.

ASF/SF2 Regulates CD3 Expression in Human T Cells
ASF/SF2 Expression Correlates Directly with CD3 Protein Levels in SLE Patients-We previously showed that the expression levels of CD3 protein in SLE patients correlate directly with levels of the WT CD3 mRNA isoform (9), and in this study, we show that ASF/SF2 promotes expression of the WT isoform (Fig. 3B). Based on these observations, we asked whether the expression levels of ASF/SF2 correlate with CD3 protein expression in SLE patients. The expression of CD3 protein is heterogeneous among SLE patients, such that many patients express variably low (20 -80% of normal) levels of CD3 chain whereas others express normal levels (26). In order to assess ASF/SF2 expression in a spectrum of CD3-low as well as CD3-normal patients, we chose patients at various stages of disease as assessed by the standardized SLE disease activity index (SLEDAI) scoring system. Six inactive patients (SLEDAI of 0) and six active patients (SLEDAI range of 2-16) were included. The active patients comprised two patients each with mild (SLEDAI 2-4), moderate (SLEDAI 5-8), and severe (SLEDAI Ͼ8) disease activity. Ten healthy age (Ϯ5 years)-, gender-, and race-matched individuals were used as controls. Expression levels of ASF/SF2 and CD3 chain were examined by Western blots followed by densitometric quantification and normalization to internal loading controls. The expression in SLE patients was then normalized to the expression level in the matched healthy individual, and values were plotted on a graph with ASF/SF2 depicted on the x axis and CD3 on the y axis (Fig.  5). There was significant direct correlation between ASF/SF2 and CD3 expression levels (Pearson's R ϭ 0.69, p ϭ 0.01), indicating that the ASF/SF2 may regulate expression of CD3 chain in SLE. These findings further support our data indicating that ASF/SF2 plays a role in the expression of CD3 chain and may be employed by the T cells to modulate the levels of CD3 chain in a variety of physiologic and pathologic conditions.

DISCUSSION
In this study, we present several novel findings. First, we have identified the splicing protein ASF/SF2 binding to the human T cell CD3 3Ј-UTR (Fig. 1); second, we show that ASF/SF2 represses the alternative splicing of the CD3 3Ј-UTR and promotes generation of the stable WT isoform (Figs. 2 and 3); third, we show that T cell activation leads to repression of the CD3 3Ј-UTR alternative splicing associated with increased expression of ASF/SF2 levels (Fig. 4); and finally, we show a significant direct correlation between ASF/SF2 and CD3 protein expression in SLE patients (Fig. 5).
During T cell activation, WT CD3 mRNA levels increase, whereas production of the AS isoform is repressed (Fig. 4, A and  B) and ASF/SF2 levels increase concomitantly, showing that preferential splicing regulates CD3 expression levels. Additionally, increased transcription and mRNA stability following T cell activation in the presence of costimulatory signals may also contribute to increased WT CD3 mRNA expression, as FIGURE 4. Increased ASF/SF2 levels are associated with increased WT CD3 mRNA during T cell activation. T cells were stimulated with ␣-CD3, ␣-CD28, and cross-linker antibodies for 0, 3, 6, 24, 48, and 72 h. Cells were harvested, and total protein and RNA were extracted. A, total RNA was used in RT-PCR for the CD3 3Ј-UTR and GAPDH. Data represent one of three experiments. B, WT and AS CD3 isoform expressions were quantified, normalized to GAPDH, and expressed as a ratio. The graph shows mean Ϯ S.D. from three independent experiments. C, total protein from activated cells was used in Western blots for ASF/SF2 and ␤-actin. D, graph shows ASF/SF2 protein levels normalized to ␤-actin from three independent experiments. Error bars, S.D. FIGURE 5. ASF/SF2 expression directly correlates with CD3 chain expression in SLE patients. T cells from SLE patients and healthy individuals were lysed, and total protein was used in Western blots for ASF/SF2, CD3 chain, and ␤-actin. Quantification of ASF/SF2 and CD3 expression were normalized to ␤-actin. The ASF/SF2 and CD3 values from SLE patients were normalized to the corresponding values from healthy subjects. These relative values are plotted on an x/y axis such that each dot represents one SLE patient's expression of ASF/SF2 on the x axis and CD3 on the y axis.
ASF/SF2 is known to regulate RNA stability of the PKCI-1related mRNA (29) and is also involved in translation (30), and it is not known whether ASF/SF2 may also regulate stability and translation of CD3. Our results from the oligonucleotide pulldown assay revealed that certain heterogeneous nuclear ribonuclear proteins (A1, A0, A2/B1, and G) also putatively bind to the ARE2-bearing region of the CD3 3Ј-UTR, which may also be involved in the mRNA processing of CD3. Further studies are needed to address whether these proteins may regulate CD3 expression.
We observed a significant direct correlation between ASF/ SF2 levels and CD3 protein expression in SLE patients; CD3low patients were ASF/SF2-low, whereas the CD3-normal patients were ASF/SF2-normal (Fig. 5). ASF/SF2 phosphorylation and dephosphorylation are important determinants of its splicing activity. At this point, we do not know whether phosphorylation status and other functions of ASF/SF2, such as RNA binding, nucleus to cytoplasm transport, and protein-protein interactions are also aberrant in SLE patients.
Aberrant expression of alternatively spliced isoforms of other genes is frequently observed in patients with SLE and includes the transcription factor cyclic AMP-response element modulator (CREM) (31) and the adhesion molecule CD44 (32). CREM alternative splicing produces the repressor (CREM-␣) or the activator (CREM-tau2␣) isoforms and is regulated by the SR family member SRp40 in human myometrial cells (33). It is not known whether ASF/SF2 is involved in the increased expression of the CREM-␣ isoform in SLE T cells. CD44 expression is increased in SLE patients (32) and is known to undergo extensive alternative splicing of variable (v) exons, and protein products of the CD44 v3 and CD44 v6 isoforms were observed in T cells infiltrating the kidneys of an SLE patient with nephritis (34). It is not known whether ASF/SF2 regulates CD44 alternative splicing.
Alternative splicing plays a key role in the generation of viral proteins during infection, and ASF/SF2 has been shown to regulate pre-mRNA splicing of HIV-1 (35). Such hijacking of host splicing factors by viruses may result in aberrant expression and/or modification of these proteins. Indeed, the human papilloma virus type 16 E2 protein has been shown to transactivate the promoter of ASF/SF2 (36). Aberrations may also include post-translational modifications of splicing proteins during viral infections, which may result in a break in immune tolerance to these self-proteins and trigger autoimmune cellular and antibody responses. Indeed, Epstein-Barr virus has been proposed to be involved in the expression of SLE (37), and sera from patients with SLE contain autoantibodies against SR splicing factors (38).
Because ASF/SF2 is important in the regulation of tumor suppressor, apoptosis-related, and cell-cycling genes, elevated levels have been reported in various cancers, and the encoding SFRS1 gene was recently confirmed to be a proto-oncogene (39). The dependence of viruses on ASF/SF2 and its oncogenic potential makes ASF/SF2 an attractive target for therapy in infections and cancer. Indeed, IDC-16, a small molecule inhibitor of ASF/SF2 activity, was shown to reduce human immuno-deficiency virus replication (40). Furthermore, ASF/SF2 was specifically up-regulated in a cell line model of cervical tumor progression (41), suggesting its potential as a biomarker for cancer. In our small cohort of patients, low levels of ASF/SF2 tended to correlate with increased disease activity (data not shown), suggesting that it may be exploited as a potential disease biomarker.
In conclusion, we have shown that ASF/SF2 is involved in the regulation of CD3 chain expression in human T cells and may represent a molecular mechanism for the defective expression of CD3 chain in SLE patients.